OBJECTIVES: To determine the prevalence of vitamin D deficiency (25-hydroxy vitamin D [25-OHD] levels in plasma <30 ng/mL) in pediatric patients with cystic fibrosis (CF), elucidate contributing factors for vitamin D deficiency, and determine the efficacy of ergocalciferol repletion strategies. STUDY DESIGN: Retrospective chart review of 262 pediatric patients from January 2003 to December 2006 with linear and logistic regression analyses. RESULTS: Vitamin D deficiency prevalence declined in the years studied from 86.5% to 46.2%. Patients >12 years old were more likely to have deficiency than patients <5 years old (odds ratio [OR], 3.44; 95% CI, 1.73-6.84). Levels obtained in spring and summer were less likely to be deficient compared with those obatained in fall (OR, 0.24; 95% CI, 0.10-0.61; and OR, 0.25; 95% CI, 0.11-0.61; respectively). Success of treatment with 50,000 IU of ergocalciferol once, twice, or 3 times weekly was 33%, 26%, and 43%, respectively. Ergocalciferol, when compared with no treatment, did not significantly increase the proportion of patients with follow-up levels > or =30 ng/mL (chi(2)P value = .80, .34, and .22, respectively). CONCLUSIONS: The prevalence of vitamin D deficiency is high, but declined with time. Age, forced expiratory volume in 1 second, and season were associated with 25-OHD levels. Despite 33% of patients responding to 50 000 IU of ergocalciferol once a week, this recommendation does not adequately treat most patients with CF who have vitamin D deficiency.
OBJECTIVES: To determine the prevalence of vitamin D deficiency (25-hydroxy vitamin D [25-OHD] levels in plasma <30 ng/mL) in pediatric patients with cystic fibrosis (CF), elucidate contributing factors for vitamin D deficiency, and determine the efficacy of ergocalciferol repletion strategies. STUDY DESIGN: Retrospective chart review of 262 pediatric patients from January 2003 to December 2006 with linear and logistic regression analyses. RESULTS:Vitamin D deficiency prevalence declined in the years studied from 86.5% to 46.2%. Patients >12 years old were more likely to have deficiency than patients <5 years old (odds ratio [OR], 3.44; 95% CI, 1.73-6.84). Levels obtained in spring and summer were less likely to be deficient compared with those obatained in fall (OR, 0.24; 95% CI, 0.10-0.61; and OR, 0.25; 95% CI, 0.11-0.61; respectively). Success of treatment with 50,000 IU of ergocalciferol once, twice, or 3 times weekly was 33%, 26%, and 43%, respectively. Ergocalciferol, when compared with no treatment, did not significantly increase the proportion of patients with follow-up levels > or =30 ng/mL (chi(2)P value = .80, .34, and .22, respectively). CONCLUSIONS: The prevalence of vitamin D deficiency is high, but declined with time. Age, forced expiratory volume in 1 second, and season were associated with 25-OHD levels. Despite 33% of patients responding to 50 000 IU of ergocalciferol once a week, this recommendation does not adequately treat most patients with CF who have vitamin D deficiency.
Authors: Jessica A Alvarez; Elizabeth Y Chong; Douglas I Walker; Joshua D Chandler; Ellen S Michalski; Ruth E Grossmann; Karan Uppal; Shuzhao Li; Jennifer K Frediani; Rabindra Tirouvanziam; ViLinh T Tran; Vin Tangpricha; Dean P Jones; Thomas R Ziegler Journal: Metabolism Date: 2017-02-11 Impact factor: 8.694
Authors: Natasha B Khazai; Suzanne E Judd; Leo Jeng; Linda L Wolfenden; Arlene Stecenko; Thomas R Ziegler; Vin Tangpricha Journal: J Clin Endocrinol Metab Date: 2009-03-31 Impact factor: 5.958
Authors: Helen M Pappa; Paul D Mitchell; Hongyu Jiang; Sivan Kassiff; Rajna Filip-Dhima; Diane DiFabio; Nicolle Quinn; Rachel C Lawton; Mark Varvaris; Stephanie Van Straaten; Catherine M Gordon Journal: J Clin Endocrinol Metab Date: 2012-03-28 Impact factor: 5.958
Authors: James L Kreindler; Chad Steele; Nikki Nguyen; Yvonne R Chan; Joseph M Pilewski; John F Alcorn; Yatin M Vyas; Shean J Aujla; Peter Finelli; Megan Blanchard; Steven F Zeigler; Alison Logar; Elizabeth Hartigan; Marcia Kurs-Lasky; Howard Rockette; Anuradha Ray; Jay K Kolls Journal: J Clin Invest Date: 2010-08-16 Impact factor: 14.808
Authors: Chiara Bertolaso; Veronique Groleau; Joan I Schall; Asim Maqbool; Maria Mascarenhas; Norma E Latham; Kelly A Dougherty; Virginia A Stallings Journal: J Pediatr Gastroenterol Nutr Date: 2014-04 Impact factor: 2.839
Authors: Laura A McCauley; William Thomas; Theresa A Laguna; Warren E Regelmann; Antoinette Moran; Lynda E Polgreen Journal: Ann Am Thorac Soc Date: 2014-02